Loading...
XKRX
004720
Market cap52mUSD
Dec 05, Last price  
4,165.00KRW
1D
0.85%
1Q
-5.23%
Jan 2017
-75.86%
Name

PharmGen Science Inc

Chart & Performance

D1W1MN
XKRX:004720 chart
P/E
27.56
P/S
0.45
EPS
151.12
Div Yield, %
—
Shrs. gr., 5y
13.54%
Rev. gr., 5y
12.48%
Revenues
171.29b
+2.70%
78,559,320,00077,680,145,00048,740,944,00043,926,893,00027,911,913,08030,291,620,67038,971,052,56044,203,012,42060,405,445,20071,545,613,18079,894,496,57089,101,640,00095,137,668,55096,614,310,440109,866,066,810150,930,715,370166,778,825,650171,286,610,000
Net income
2.79b
-51.27%
-221,835,000-11,315,404,000-1,946,753,000-2,765,635,000-8,823,738,000-5,231,609,800-3,698,557,000-4,583,680,0002,067,281,0003,452,135,9304,319,900,3104,467,984,120235,995,6009,222,178,37032,465,959,37070,059,662,0405,727,238,8302,790,819,000
CFO
2.38b
-56.16%
-5,533,603,0003,823,582,000-14,702,708,000628,491,0002,893,279,980-3,975,637,310-4,204,856,380-2,016,894,3203,621,572,7407,754,655,7901,837,763,3804,215,582,0902,523,396,0002,675,611,6407,784,092,730-1,286,177,4105,438,941,4492,384,289,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It offers prescription drugs, OTC drugs, health food, and cosmetics. It offers its products in the form of tablet, hard capsule, granule and ointment, syrups, and suspension forms. The company was formerly known as Wooridul Pharmaceutical Limited and changed its name to PharmGen Science, Inc. PharmGen Science, Inc. was founded in 1961 and is headquartered in Hwaseong, South Korea.
URL
http://www.wooridulpharm.com/
IPO date
Jun 15, 1990
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT